MCRN 002 – The STOMP Trial
Led by Dr Nizar Bahlis in Calgary and Dr Christine Chen in Toronto, The STOMP Trial is playing a principal role in the clinical development of a promising new molecule, selinexor (KPT-330), a first-in-class selective inhibitor of nuclear export (SINE™) compound developed by Karyopharm Therapeutics. This has given eligible patients across Canada early access to the innovative therapy.
The Phase II trial combines selinexor, with dexamethasone and a "backbone" therapy: either bortezomib (Velcade®), lenalidomide (Revlimid®) or pomalidomide (Pomalyst®) in patients with relapsed or refractory myeloma. The therapies are given orally, with the exception of bortezomib, which is given by subcutaneous injection.
More than 75 patients in the following Canadian centres have thus far participated in the trial:
- Calgary – Tom Baker Cancer Centre
- Edmonton – Cross Cancer Institute
- Halifax – Queen Elizabeth II Health Sciences Centre
- Montreal – Maisonneuve-Rosemont Hospital
- Montreal – Royal Victoria Hospital/McGill University
- Regina – Saskatchewan Cancer Agency - Allan Blair Cancer Centre
- St John's – Memorial Hospital of Newfoundland,
- Toronto – Princess Margaret Cancer Centre
- Vancouver – Vancouver General Hospital
- Winnipeg – CancerCare Manitoba